ArticleOncoTargets and therapy2017

Optimizing the treatment of bevacizumab as first-line therapy for human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer: an updated meta-analysis of published randomized trials.

Cunfu Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.